2022 KAPAL–KHIDI Bio & Health Webinar Series는 한미생명과학인 협회 (KAPAL)와 KHIDI 미국지사 웨비나 시리즈입니다.
Topic Title: Advantages & strategies for breaking into the West Coast-based U.S market |Sacramento & Los Angeles
KAPAL-CA is hosting a special seminar for Korean biotech & life sciences companies looking to enter the West Coast-based U.S market. As many people are aware, San Francisco and San Diego comprise the largest biotech clusters in the West Coast region. To bring forth different perspectives and introduce nascent and promising regions within California, KAPAL-CA has invited two qualified speakers who can articulate the benefits of Sacramento & Los Angeles as alternative options for Korean companies’ U.S. base of operations.
Invited Speakers: Troels Adrian | VP of Business Development, Greater Sacramento Economic Council Dave Whelan | CEO, BioscienceLA
이번에 KAPAL 과 KASBP Washington DC Chapter 가 함께 준비한 Joint Networking Dinner 에 여러분을 초대합니다. 코로나 바이러스 팬데믹 동안 못보신 분들과 서로의 안부도 묻고 맛있는 저녁도 함께 드시면서 좋은 말씀 나누시는 기회가 되시기를 진심으로 바랍니다. 석식준비를 위해 등록을 부탁드립니다. 이미 등록을 하셨으면 감사드리고 당일에 꼭 참석해주시기를 부탁드립니다. 혹시 부득이한 사정으로 등록하셨는데 데 참석을 못하실 경우 꼭 등록 취소는 contact@kapal.org 로 간단히 이멜 부탁드립니다.
Hello, you are cordially invited to the 2022 KAPAL-KASBP Washington DC Chapter Joint Networking Dinner, which will be held on July 21, 2022 at 6 pm. There will be Korean catering dinner and drinks ready for you and your colleagues. If you have any questions related to the registration or event, please email to contact@kapal.org (KAPAL) or calciumhwang@gmail.com (KASBP DC Chapter). Please share this invitation with your colleagues and come to join the 2022 KAPAL-KASBP Washington DC Chapter Joint Networking Dinner.
— Private professional adult-only event. — Event will be held in Korean/English
Sung provides counsel to FDA-regulated companies in developing, distributing, and marketing FDA-regulated digital health products and, when necessary, in responding to regulatory and administrative enforcement actions by federal and state agencies. Sung frequently counsels clients on FDA’s legal and regulatory requirements and policies for digital health products, and provides counsel that allows companies to comply with FDA’s policies and requirements. Sung has experience in responding to FDA’s various enforcement actions such as warning letters, untitled letters, and form 483 notice of inspectional observations. Sung understands the unique business landscape of FDA-regulated products, and provides practical advice that suits the needs of the client’s business.
발표 II : 윤학희 CEO (Harry Yun) / InBody USA
Harry Yun is the CEO of InBody USA, a prominent medical device company from Korea and a worldwide leader in body composition technology with a mission to provide biomedical technology that simplifies the understanding of health and wellness. InBody USA was established in the year 2000 in Beverly Hills, California and has moved its corporate office to Cerritos, California in 2012. Under Yun’s leadership, InBody continues to successfully penetrate the US market with state-of-the-art technology. Yun is a graduate from Hankuk University of Foreign Studies (HUFS) with Masters in Economics and has extensive experience of International Marketing.
발표 III : 조성환 CTO (Sunghwan Cho) / NanoCellect Biomedical Inc
Sunghwan Cho is the CTO of NanoCellect Biomedical Inc, whose mission is to facilitate breakthrough biomedical discoveries by making cell analysis and sorting technology more affordable and easier to use. He has 15+ years of expertise in integrating microfluidics, optics, micro/nano-fabrication, and electronics for advanced biomedical devices and instruments. He is also an inventor of the company’s core technologies, including its microfluidics-based cell sorting platform, and manages the company’s research project and product development. He was selected as a Marylou Ingram Scholar of the International Society for Advancement of Cytometry (ISAC) from 2012 to 2017, recognized for his contribution to the field of cytometry.
